Navigation Links
A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer

A recent study has shown that a chemotherapy regimen combining vinorelbine (Navelbine) and mitoxantrone (Novantrone)// with the corticosteroid prednisone is effective in the treatment of hormone-refractory prostate cancer . Specialists say this treatment should be offered to symptomatic patients earlier in their disease.

However researchers added that a larger phase 2 study of this treatment regimen is planned. From a group of 66 patients who had advanced prostate cancer, the investigators recruited 12 for whom previous hormone therapy had failed in at least 3 lines of treatment.

The investigators included patients who had undergone palliative radiotherapy at any point during their disease. The patient’s median age was 67 years, with a range of 60 to 81 years. The patient’s median Eastern Cooperative Oncology Group performance status was 1, with a range of 0 to 2. All the patients had bone metastases, some with multiple sites. One patient had lymph node metastasis, and 1 had visceral disease. Three patients had significant ischaemic heart disease.

Each treatment cycle consisted of 10 to 12 mg/m2 of mitoxantrone on day 1, followed by 20 mg/m2 of vinorelbine on days 1 through 8. This cycle was repeated every 3 weeks. The patients also received 12.5 mg daily of prednisone. A total of 95 cycles were given, with a median of 7 cycles per patient and a range of 5 to 9 cycles per patient. Two patients repeated the treatment at 6 months and 12 months after the initial treatment. Among these patients, 50% had a marked decrease in pain and improvement in ECOG performance status, according to specialists. In 8 cycles, due to the response to treatment, the dose of vinorelbine was reduced 50% and in 4 cycles it was reduced 75%. The mitoxantrone dose was reduced 50% in 5 cycles. Although 1 patient had a drop in prostate specific antigen (PSA) of more than 50%, the computed tomography findings did not show an equivalent response.

The patients' median time to progression was 10 months, with a range of 6 months to over 20 months. Two patients are living; 8 died due to disease progression; and 2 died of other causes. The toxicity episodes consisted of 6 neutropaenic events, all afebrile. Otherwise, the investigators documented no Grade 4 haematological toxicity and no non-haematological toxicity.
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Drug Combinations May Boost Stroke Risk
3. Combination therapy to treat breast cancer
4. Combination regime may work against prostate cancer
5. Smoking and Breast Cancer - A Deadly Combination
6. New Drug Combination Found To Improve Memory in Alzheimer’s Patient
7. Combination Therapy Effective In Improving Lung Cancer Survival
8. Combination Therapy Found To Improves Stroke Recovery
9. Combination Therapy Found To Be More Effective In Treating Brain Cancer
10. Combination of Clopidogrel-aspirin is better for preventing stroke than only aspirin
11. New Combination Therapy Option for HIV Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, ... lowdown on sciatica in a new episode of "Success Files," which is an ... and innovation and investigates each subject in-depth with passion and integrity. , Sciatica ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 The Rebound mobile app is ... to reverse the tide of prescription drug addiction. The app ... medicine intake and stepping down their dosage in a safe, ... in December 2017; the first 100,000 people to sign up ... http://www.rebound-solution.com/ ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
Breaking Medicine Technology: